WO2021043220A1 - 抗cd47的单克隆抗体及其用途 - Google Patents

抗cd47的单克隆抗体及其用途 Download PDF

Info

Publication number
WO2021043220A1
WO2021043220A1 PCT/CN2020/113287 CN2020113287W WO2021043220A1 WO 2021043220 A1 WO2021043220 A1 WO 2021043220A1 CN 2020113287 W CN2020113287 W CN 2020113287W WO 2021043220 A1 WO2021043220 A1 WO 2021043220A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
amino acid
sequence
antibody
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2020/113287
Other languages
English (en)
French (fr)
Chinese (zh)
Inventor
张鹏
李百勇
夏瑜
王忠民
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akeso Pharmaceuticals Inc
Original Assignee
Akeso Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2022002505A priority Critical patent/MX2022002505A/es
Priority to AU2020342192A priority patent/AU2020342192A1/en
Priority to BR112022003868A priority patent/BR112022003868A2/pt
Priority to JP2022513964A priority patent/JP7808546B2/ja
Priority to EP20861103.8A priority patent/EP4026847A4/en
Priority to CA3148956A priority patent/CA3148956A1/en
Priority to US17/640,005 priority patent/US12703743B2/en
Priority to KR1020227010974A priority patent/KR20220053665A/ko
Application filed by Akeso Biopharma Inc filed Critical Akeso Biopharma Inc
Priority to PH1/2022/550489A priority patent/PH12022550489A1/en
Publication of WO2021043220A1 publication Critical patent/WO2021043220A1/zh
Priority to IL291049A priority patent/IL291049A/en
Anticipated expiration legal-status Critical
Priority to ZA2022/03622A priority patent/ZA202203622B/en
Priority to JP2025072311A priority patent/JP2025114620A/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Definitions

  • the present invention relates to the field of autoimmune disease treatment and molecular immunology. It relates to an anti-CD47 antibody, a pharmaceutical composition containing the same, and uses thereof. Specifically, the present invention relates to an anti-CD47 monoclonal antibody.
  • CD47 is also known as integrin-associated protein (IAP).
  • IAP integrin-associated protein
  • CD47 is a 5-pass transmembrane protein with a molecular weight of about 50kDa and belongs to the immunoglobulin superfamily. Its extracellular N-terminal is the IgV domain, which is connected to ⁇ v ⁇ 3 (CD51/CD61) and ⁇ IIb ⁇ 3 (CD41/CD61) integrins.
  • CD47 is involved in a variety of physiological functions, such as cell transfer, T cell and dendritic cell (DC) activation, axon development and other functions.
  • DC dendritic cell
  • CD47 is expressed on all cell types including red blood cells, and CD47 is highly expressed on tumor cells.
  • CD47 has two ligands: Signal Regulatory Protein ⁇ (SIRP ⁇ ) and Thrombospondin-1 (Thrombospondin-1, TSP1).
  • SIRP ⁇ is a type of receptor penetrating glycoprotein containing immunoglobulin domains. It belongs to the SIRP family and is mainly expressed on macrophages and nerve cells.
  • CD47 protein binds to SIRP ⁇ to phosphorylate its immunoreceptor tyrosine inhibitory motif ITIM, and then recruit SHP-1 protein in the cell, producing a series of cascade reactions that inhibit macrophage phagocytosis Matozaki T, Murata Y, Okazawa H, et al. Functions and molecular mechanisms of the CD47-SIRP ⁇ signaling pathway. Trends in cell biology, 2009, 19(2): 72-80.). Normal red blood cells are not phagocytosed due to the binding of CD47 on the cell membrane surface and SIPR ⁇ of macrophages to produce inhibitory signals.
  • TSP1 is a homotrimer composed of 3 peptide chains, which interacts with other cell surface receptors, matrix components and growth factors to participate in cell proliferation, apoptosis, adhesion, migration, angiogenesis and other processes (Jiang P, Lagenaur CF, Narayanan V. Integrin-associated Protein Is a Ligand for the P84 Neural Adhesion Molecule. Journal of Biological Chemistry 1999.274: 559-62).
  • Macrophages are derived from monocytes, and monocytes are derived from precursor cells in the bone marrow. The main function is to phagocytose cell fragments and pathogens in the form of fixed cells or free cells and activate lymphocytes or other immune cells to make them respond to pathogens. Current studies believe that tumor cells have a mechanism to escape macrophages.
  • anti-CD47 antibodies kill tumor cells mainly through two mechanisms. 1. The combination of anti-CD47 antibody and CD47 blocks the CD47-SIRP ⁇ pathway and allows macrophages to exert phagocytosis. 2. Anti-CD47 antibody exerts tumor-killing effect through DC cells and CD8+T cells. Through the synergistic effect of anti-CD47 antibodies and pro-phagocytic molecules such as calreticulin, DC cells phagocytose tumor cells and present tumor-associated antigens to CD8+ T cells, thereby exerting the specific killing effect of CD8+ T cells on tumors (CD47 blockade as another immune) checkpoint therapy for cancer. Vonderheide R H. Nature Medicine, 2015, 21(10): 1122). The combination of these two mechanisms indicates that anti-CD47 antibodies are very likely to have the ability to simultaneously activate non-specific immunity and specific immunity.
  • anti-CD47 monoclonal antibody drugs have broad application prospects and good tumor treatment effects, and can be used for the treatment of various tumors.
  • the anti-CD47 monoclonal antibody drug Hu5F9-G4 can effectively inhibit the growth and metastasis of hematological malignancies and solid tumors in preclinical experiments (Abstract PR13:
  • the anti-CD47 antibody Hu5F9-G4 is a novel immune checkpoint inhibitor with synergistic efficiency in combination with clinically active cancer targeting antibodies[J] Chao M P, McKenna K M, Cha A, et al., 2016).
  • the inventors used a mammalian cell expression system to express recombinant human CD47, which was used as an antigen to immunize mice, and hybridoma cells were obtained by fusion of mouse spleen cells and myeloma cells. Through the screening of a large number of samples, the following hybridoma cell lines were obtained.
  • the hybridoma cell line LT012 can secrete a monoclonal antibody that specifically binds to CD47 (named 6F7), and this monoclonal antibody can compete with the receptor SIRP ⁇ ECD-hFc-Biotin for binding to CD47, effectively blocking the binding of SIRP ⁇ to CD47, and then Promote the phagocytosis of tumor cells by macrophages.
  • the present inventors prepared humanized antibodies of monoclonal antibody 6F7 (named 6F7H1L1, 6F7H2L2 and 6F7H3L3).
  • the present invention thus provides the following inventions:
  • One aspect of the present invention relates to antibodies or antigen-binding fragments thereof, wherein:
  • the antibody comprises a CDR sequence selected from the following heavy chain variable region and light chain variable region
  • HCDR1, HCDR2 and HCDR3 contained in the heavy chain variable region shown in SEQ ID NO: 2, and
  • SEQ ID NO: LCDR1, LCDR2, and LCDR3 contained in the light chain variable region shown in SEQ ID NO: 4;
  • the light chain variable region shown in SEQ ID NO: 14 includes LCDR1, LCDR2 and LCDR3; or
  • SEQ ID NO: LCDR1, LCDR2, and LCDR3 contained in the light chain variable region shown in SEQ ID NO: 18;
  • the light chain variable region shown in SEQ ID NO: 22 includes LCDR1, LCDR2 and LCDR3;
  • the antibody comprises:
  • HCDR1 which includes the sequence shown in SEQ ID NO: 5, has at least 80% of the sequence, preferably 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% , 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or more than 99% sequence identity sequence, or compared with the sequence has one or more ( Preferably 1, 2, or 3) conservative amino acid mutations (preferably substitutions, insertions or deletions) of amino acid sequences, or consisting of them,
  • HCDR2 which includes the sequence shown in SEQ ID NO: 6, has at least 80% of the sequence, preferably 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% , 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or more than 99% sequence identity sequence, or compared with the sequence has one or more ( Preferably 1, 2 or 3) conservative amino acid mutations (preferably substitutions, insertions or deletions) of amino acid sequences, or consisting of them, and
  • HCDR3 which includes the sequence shown in SEQ ID NO: 7, has at least 80%, preferably 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% of the sequence. , 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or more than 99% sequence identity sequence, or compared with the sequence has one or more ( Preferably, 1, 2, or 3) conservative amino acid mutations (preferably substitutions, insertions or deletions) of amino acid sequences, or consisting of them, and the antibody further comprises:
  • LCDR1 which contains the amino acid shown in SEQ ID NO: 8, or has at least 80% of the sequence, preferably 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89 %, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or more than 99% sequence identity sequence, or compared with the sequence has one or more (Preferably 1, 2 or 3) amino acid sequence of conservative amino acid mutation (preferably substitution, insertion or deletion), or consisting of it,
  • LCDR2 which includes the amino acid sequence shown in SEQ ID NO: 9, has at least 80%, preferably 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89 %, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or more than 99% sequence identity sequence, or compared with the sequence has one or more (Preferably 1, 2 or 3) conservative amino acid mutations (preferably substitutions, insertions or deletions) of amino acid sequences, or consisting of them, and
  • LCDR3 which contains the sequence shown in SEQ ID NO: 10, has at least 80% of the sequence, preferably 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% , 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or more than 99% sequence identity sequence, or compared with the sequence has one or more ( Preferably, 1, 2, or 3) conservative amino acid mutations (preferably substitutions, insertions or deletions) of amino acid sequences, or consisting of them.
  • the antibody includes:
  • variable region of the heavy chain which comprises or consists of the following sequence:
  • SEQ ID NO: the amino acid sequence shown in 2, or
  • sequence shown in SEQ ID NO: 2 has at least 85%, preferably 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97 %, 98% or more than 99% sequence identity sequence, or
  • amino acid sequence shown in SEQ ID NO: 2 it has one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30) amino acid sequence of conservative amino acid mutations (preferably substitutions, insertions or deletions), and
  • variable region of the light chain which comprises or consists of the following sequence:
  • SEQ ID NO: the amino acid sequence shown in 4, or
  • sequence shown in SEQ ID NO: 4 has at least 85%, preferably 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97 %, 98% or more than 99% sequence identity sequence, or
  • amino acid sequence shown in SEQ ID NO: 4 it has one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30) amino acid sequence of conservative amino acid mutations (preferably substitutions, insertions or deletions);
  • variable region of the heavy chain which contains or consists of the following sequence:
  • sequence shown in SEQ ID NO: 12 has at least 85%, preferably 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97 %, 98% or more than 99% sequence identity sequence, or
  • amino acid sequence shown in SEQ ID NO: 12 Compared with the amino acid sequence shown in SEQ ID NO: 12, it has one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30) amino acid sequence of conservative amino acid mutations (preferably substitutions, insertions or deletions), and
  • variable region of the light chain which comprises or consists of the following sequence:
  • sequence shown in SEQ ID NO: 14 has at least 85%, preferably 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97 %, 98% or more than 99% sequence identity sequence, or
  • amino acid sequence shown in SEQ ID NO: 14 it has one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30) amino acid sequence of conservative amino acid mutations (preferably substitutions, insertions or deletions);
  • sequence shown in SEQ ID NO: 16 has at least 85%, preferably 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97 %, 98% or more than 99% sequence identity sequence, or
  • amino acid sequence shown in SEQ ID NO: 16 it has one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30) amino acid sequence of conservative amino acid mutations (preferably substitutions, insertions or deletions), and
  • variable region of the light chain which comprises or consists of the following sequence:
  • sequence shown in SEQ ID NO: 18 has at least 85%, preferably 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97 %, 98% or more than 99% sequence identity sequence, or
  • amino acid sequence shown in SEQ ID NO: 18 Compared with the amino acid sequence shown in SEQ ID NO: 18, it has one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30) amino acid sequence of conservative amino acid mutations (preferably substitutions, insertions or deletions);
  • variable region of the heavy chain which comprises or consists of the following sequence:
  • sequence shown in SEQ ID NO: 20 has at least 85%, preferably 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97 %, 98% or more than 99% sequence identity sequence, or
  • amino acid sequence shown in SEQ ID NO: 20 Compared with the amino acid sequence shown in SEQ ID NO: 20, it has one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30) amino acid sequence of conservative amino acid mutations (preferably substitutions, insertions or deletions), and
  • variable region of the light chain which comprises or consists of the following sequence:
  • sequence shown in SEQ ID NO: 22 has at least 85%, preferably 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97 %, 98% or more than 99% sequence identity sequence, or
  • amino acid sequence shown in SEQ ID NO: 22 Compared with the amino acid sequence shown in SEQ ID NO: 22, it has one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, The amino acid sequence of 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30) conservative amino acid mutations (preferably substitutions, insertions or deletions).
  • the antibodies 6F7, 6F7H1L1, 6F7H2L2 and 6F7H3L3 of the present invention have the same HCDR1-3 and LCDR1-3:
  • amino acid sequences of the three CDR regions of the heavy chain variable region are as follows:
  • HCDR1 GYTFTSYW (SEQ ID NO: 5),
  • HCDR2 IDPSDSET (SEQ ID NO: 6),
  • HCDR3 ARLYRWYFDV (SEQ ID NO: 7);
  • amino acid sequences of the 3 CDR regions of the light chain variable region are as follows:
  • LCDR1 EIVGTY (SEQ ID NO: 8),
  • LCDR3 GQSYNFPYT (SEQ ID NO: 10).
  • the antibodies of the invention are selected from the group consisting of:
  • the antibody (preferably the 6F7 antibody) further comprises the framework region FR of the heavy chain variable region.
  • the framework region FR comprises FR-H1, FR-H2, FR-H3 and FR -H4, where FR-H1 includes the amino acid sequence of SEQ ID NO: 23 or has at least 80% of the sequence shown in SEQ ID NO: 23, preferably 81%, 82%, 83%, 84%, 85%, 86% , 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or more than 99% sequence identity, or with SEQ ID Compared with the amino acid sequence shown in NO: 23, there are one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) conservative amino acid mutations (preferably substitutions, insertions or deletions)
  • FR-H2 includes the amino acid sequence of SEQ ID NO: 24 or has at least 80% of the sequence shown in SEQ ID NO: 24 or
  • the antibody (preferably the 6F7 antibody) further comprises the framework region FR of the light chain variable region.
  • the framework region FR comprises FR-L1, FR-L2, FR-L3 and FR -L4, where FR-L1 includes the amino acid sequence of SEQ ID NO: 27 or has at least 80% of the sequence shown in SEQ ID NO: 27, preferably 81%, 82%, 83%, 84%, 85%, 86% , 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or more than 99% sequence identity, or with SEQ ID Compared with the amino acid sequence shown by NO: 27, there are one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) conservative amino acid mutations (preferably substitutions, insertions or deletions)
  • FR-L2 includes the amino acid sequence of SEQ ID NO: 28 or has at least 80% of the sequence shown in SEQ ID NO:
  • the antibody (preferably the 6F7 H1L1 antibody) further comprises the framework region FR of the heavy chain variable region.
  • the framework region FR comprises FR-H1, FR-H2, FR-H3 and FR-H4, where FR-H1 includes the amino acid sequence of SEQ ID NO: 31, or has at least 80% of the sequence shown in SEQ ID NO: 31, preferably 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or more than 99% sequence identity, or with Compared with the amino acid sequence shown in SEQ ID NO: 31, there are one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) conservative amino acid mutations (preferably substitutions, insertions or deletions) ), or consist of it; FR-H2 includes the amino acid sequence of SEQ ID NO: 32, or has at least 80%, preferably 81%, 8
  • the antibody (preferably the 6F7H1L1 antibody) further comprises the framework region FR of the light chain variable region.
  • the framework region FR comprises FR-L1, FR-L2, FR-L3 and FR -L4, where FR-L1 includes the amino acid sequence of SEQ ID NO: 35, or has at least 80% of the sequence shown in SEQ ID NO: 35, preferably 81%, 82%, 83%, 84%, 85%, 86 %, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or more than 99% sequence identity, or with SEQ ID NO:
  • the amino acid sequence shown in 35 has one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) conservative amino acid mutations (preferably substitutions, insertions or deletions)
  • FR-L2 includes the amino acid sequence of SEQ ID NO: 36, or has at least 80% of the sequence shown in SEQ ID NO: 36,
  • the antibody (preferably the 6F7H2L2 antibody) further comprises the framework region FR of the heavy chain variable region.
  • the framework region FR comprises FR-H1, FR-H2, FR-H3 and FR -H4, where FR-H1 includes the amino acid sequence of SEQ ID NO: 39, or has at least 80% of the sequence shown in SEQ ID NO: 39, preferably 81%, 82%, 83%, 84%, 85%, 86 %, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or more than 99% sequence identity, or with SEQ ID NO:
  • FR-H2 includes the amino acid sequence of SEQ ID NO: 40, or has at least 80% of the sequence shown in SEQ ID NO:
  • the antibody (preferably the 6F7H2L2 antibody) further comprises the framework region FR of the light chain variable region.
  • the framework region FR comprises FR-L1, FR-L2, FR-L3 and FR -L4, where FR-L1 includes the amino acid sequence of SEQ ID NO: 43, or has at least 80% of the sequence shown in SEQ ID NO: 43, preferably 81%, 82%, 83%, 84%, 85%, 86 %, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or more than 99% sequence identity, or with SEQ
  • the amino acid sequence shown in ID NO: 43 has or consists of one or more conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to the amino acid sequence shown in ID NO: 43;
  • FR-L2 includes the amino acid sequence of SEQ ID NO: 44, or The sequence shown in SEQ ID NO: 44 has at least
  • the antibody (preferably the 6F7H3L3 antibody) further comprises the framework region FR of the heavy chain variable region.
  • the framework region FR comprises FR-H1, FR-H2, FR-H3 and FR -H4, where FR-H1 includes the amino acid sequence of SEQ ID NO: 47, or has at least 80% of the sequence shown in SEQ ID NO: 47, preferably 81%, 82%, 83%, 84%, 85%, 86 %, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or more than 99% sequence identity, or with SEQ ID NO:
  • the amino acid sequence shown in 47 has one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) conservative amino acid mutations (preferably substitutions, insertions or deletions)
  • FR-H2 includes the amino acid sequence of SEQ ID NO: 48, or has at least 80% of the sequence shown in SEQ ID NO: 48,
  • the antibody (preferably the 6F7H3L3 antibody) further comprises the framework region FR of the light chain variable region.
  • the framework region FR comprises FR-L1, FR-L2, FR-L3 and FR -L4, where FR-L1 includes the amino acid sequence of SEQ ID NO: 51, or has at least 80% of the sequence shown in SEQ ID NO: 51, preferably 81%, 82%, 83%, 84%, 85%, 86 %, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or more than 99% sequence identity, or with SEQ ID NO:
  • the amino acid sequence shown in 51 has one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) conservative amino acid mutations (preferably substitutions, insertions or deletions)
  • FR-L2 contains the amino acid sequence of SEQ ID NO: 52, or has at least 80% of the sequence shown in SEQ ID NO: 52,
  • polypeptide in one aspect of the present invention, it relates to an isolated polypeptide comprising the sequence shown in SEQ ID NO: 5, 6 and 7, wherein the polypeptide is part of an antibody against human CD47 and specifically binds to human CD47.
  • the antibody It also contains the sequences shown in SEQ ID NO: 8, 9 and 10.
  • polypeptide in one aspect of the present invention, it relates to an isolated polypeptide comprising the sequence shown in SEQ ID NO: 8, 9 and 10, wherein the polypeptide is part of an antibody against human CD47 and specifically binds to human CD47. It also contains the sequences shown in SEQ ID NO: 5, 6 and 7.
  • an isolated polypeptide which comprises a sequence selected from SEQ ID NO: 2, 12, 16 or 20 or has at least 85% of the sequence, preferably 86%, 87%, 88% , 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or more than 99% sequence identity sequence, or compared with the sequence has one or Multiple (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30) amino acid sequence of conservative amino acid mutations (preferably substitutions, insertions or deletions), wherein the polypeptide is part of an antibody against human CD47 and specifically binds to human CD47, so
  • the antibodies also correspondingly comprise a sequence selected from SEQ ID NO: 4, 14, 18 or 22 or have at least 85% of the sequence, preferably 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%
  • an isolated polypeptide which comprises a sequence selected from SEQ ID NO: 4, 14, 18 or 22 or has at least 85% of the sequence, preferably 86%, 87%, 88% , 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or more than 99% sequence identity sequence, or compared with the sequence has one or Multiple (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30) amino acid sequence of conservative amino acid mutations (preferably substitutions, insertions or deletions), wherein the polypeptide is part of an antibody against human CD47 and specifically binds to human CD47, so
  • the monoclonal antibody also correspondingly comprises a sequence selected from SEQ ID NO: 2, 12, 16 or 20 or at least 85% of the sequence, preferably 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 9
  • the antigen-binding fragment is selected from the group consisting of Fab, Fab', F(ab')2, Fd, Fv, dAb, Fab/c, complementarity determining region (CDR) fragments, single-chain antibodies (e.g. , ScFv), bivalent antibodies, domain antibodies.
  • CDR complementarity determining region
  • the antibody is a humanized antibody, a chimeric antibody, a multispecific antibody (e.g., a bispecific antibody).
  • the antibody is less than about 10 -5 M, such as less than about 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M, or 10 -10 M or less KD binds to human CD47 protein.
  • the KD is measured by a Fortebio molecular interaction instrument.
  • the antibody is less than about 100 nM, such as less than about 10 nM, 1 nM, 0.9 nM, 0.8 nM, 0.7 nM, 0.6 nM, 0.5 nM, 0.4 nM, 0.3 nM, 0.2 nM, 0.1 nM or
  • the smaller EC50 binds to human CD47 protein. Specifically, the EC50 is measured by an indirect ELISA method.
  • the antibody includes a constant region, and the constant region is from a species other than murine, for example, from a human antibody, preferably from human IgG, more preferably IgG1 or IgG4.
  • the constant region of the antibody is of human origin.
  • the heavy chain constant region uses the Ig gamma-1 chain C region, more preferably the Ig gamma-1 chain C with the GenBank accession number ACCESSION: P01857 Region (SEQ ID NO: 58), or Ig gamma-4 chain C region, more preferably Ig gamma-4 chain C region (SEQ ID NO: 56) with GenBank registration number ACCESSION: P01861.1; light chain constant region
  • the Ig kappa chain C region is used, and the Ig kappa chain C region (SEQ ID N O: 57) with the GenBank registration number ACCESSION: P01834 is more preferred.
  • the antibody of the present invention uses the following constant regions based on the variable regions of 6F7 H1L1, 6F7 H2L2 and 6F7 H3L3: the heavy chain constant region is Ig gamma-1 chain C region, ACCESSION: P01857 (SEQ ID NO: 58) or heavy chain The constant region Ig gamma-4 chain C region, ACCESSION: P01861.1 (SEQ ID NO: 56); the light chain constant region is Ig kappa chain C region, ACCESSION: P01834 (SEQ ID NO: 57).
  • Another aspect of the present invention relates to an isolated polynucleotide encoding a polypeptide comprising the sequence shown in SEQ ID NO: 5, 6 and 7, wherein the polypeptide is part of an anti-human CD47 antibody that specifically binds Human CD47, the antibody also contains the sequences shown in SEQ ID NO: 8, 9 and 10.
  • polypeptide comprising the sequence shown in SEQ ID NOs: 8, 9 and 10, wherein the polypeptide is part of an antibody against human CD47 with specificity In combination with human CD47, the antibody also includes the sequences shown in SEQ ID NO: 5, 6 and 7.
  • polypeptide comprising a sequence selected from SEQ ID NO: 2, 12, 16 or 20 or having at least 85% of the sequence, preferably 86 %, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or more than 99% sequence identity
  • the sequence has one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 , 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30) conservative amino acid mutations (preferably substitutions, insertions or deletions) amino acid sequence, wherein the polypeptide is part of an antibody against human CD47, Specifically binding to human CD47, the antibody also correspondingly comprises a sequence selected from SEQ ID NO: 4, 14, 18 or 22 or has at least 85% of the sequence, preferably 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 9
  • polypeptide comprising a sequence selected from SEQ ID NO: 4, 14, 18 or 22 or at least 85% of the sequence, preferably 86 %, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or more than 99% sequence identity
  • the sequence has one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 , 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30) conservative amino acid mutations (preferably substitutions, insertions or deletions) amino acid sequence, wherein the polypeptide is part of an antibody against human CD47, Specifically binding to human CD47, the antibody also correspondingly comprises a sequence selected from SEQ ID NO: 2, 12, 16 or 20 or has at least 85% of the sequence, preferably 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%
  • the polynucleotide molecule comprises the following sequence or consists of the following sequence: the nucleotide sequence shown in SEQ ID NO: 1, SEQ ID NO: 11, SEQ ID NO: 15 or SEQ ID NO: 19 , Or with the sequence at least 85%, preferably 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% Or a sequence with more than 99% sequence identity.
  • the polynucleotide molecule comprises or consists of the following sequence: SEQ ID NO: 3, SEQ ID NO: 13, SEQ ID NO: 17 or SEQ ID NO: 21. Or the sequence has at least 85%, preferably 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or Sequence with more than 99% sequence identity.
  • Yet another aspect of the present invention relates to a vector, which comprises any one of the polynucleotide molecules described above in the present invention.
  • Yet another aspect of the present invention relates to a host cell, which comprises the polynucleotide molecule of any one of the above-mentioned polynucleotide molecules of the present invention, or the vector of the present invention.
  • Yet another aspect of the present invention relates to a method for preparing the antibody or antigen-binding fragment thereof of any one of the above of the present invention, which comprises culturing the host cell of the present invention under suitable conditions, and recovering all the antibodies from the cell culture. The steps of the antibody or its antigen-binding fragment.
  • an antibody conjugate which includes the anti-human CD47 antibody or antigen-binding fragment thereof, and a coupling part conjugated therewith, and the coupling part is a purification tag (such as His Label), cytotoxic agent, or detectable label.
  • the coupling part is a radioisotope, a luminescent substance, a colored substance, an enzyme or polyethylene glycol.
  • a multispecific antibody preferably a bispecific antibody, which includes the anti-human CD47 antibody or antigen-binding fragment thereof, and antibodies directed against other antigens and/or other epitopes or Antigen-binding fragments.
  • a fusion protein which includes the anti-human CD47 antibody or antigen-binding fragment thereof as described above.
  • kits which includes the antibody or antigen-binding fragment thereof of any one of the above in the present invention, or includes the antibody conjugate, multispecific antibody or fusion protein of the present invention.
  • the kit further includes a second antibody, which specifically recognizes the antibody or antigen-binding fragment thereof; optionally, the second antibody also includes a detectable label, such as a radioisotope, a luminescent substance, a colored Substances, enzymes or polyethylene glycols.
  • a detectable label such as a radioisotope, a luminescent substance, a colored Substances, enzymes or polyethylene glycols.
  • hybridoma cell line selected from the following and a monoclonal antibody produced therefrom: hybridoma cell line LT012, the deposit number of which is CCTCC NO: 2018135.
  • Another aspect of the present invention relates to the detection of the presence or presence of human CD47 in a sample of the antibody or antigen-binding fragment thereof or the antibody conjugate or multispecific antibody or fusion protein of the present invention as described above in any one of the present invention. Its level, or its use in preparing a kit for detecting the presence or level of human CD47 in a sample.
  • Another aspect of the present invention relates to a pharmaceutical composition, which comprises the antibody or antigen-binding fragment thereof of any one of the above in the present invention or the antibody conjugate, multispecific antibody or fusion protein of the present invention; Optionally, it also includes a pharmaceutically acceptable carrier and/or excipient.
  • Another aspect of the present invention relates to the use of the antibody or antigen-binding fragment thereof or the antibody conjugate or multispecific antibody or fusion protein of the present invention in the preparation of the following drugs:
  • the present invention relates to the use of the antibody or antigen-binding fragment thereof or the antibody conjugate or multispecific antibody or fusion protein of the present invention in the treatment of tumors or in the preparation of drugs for the treatment of tumors.
  • Another aspect of the present invention relates to an in vivo or in vitro method, including the step of applying cells containing the antibody or antigen-binding fragment thereof, the antibody conjugate, multispecific antibody or fusion protein of the present invention, Or the step of administering to a subject in need an effective amount of the antibody or antigen-binding fragment thereof of the present invention as described above, or the antibody conjugate or multispecific antibody or fusion protein of the present invention, the method is selected From the following:
  • the in vitro method is for non-therapeutic or diagnostic purposes.
  • Yet another aspect of the present invention relates to the use of the antibody or antigen-binding fragment thereof or the antibody conjugate or multispecific antibody or fusion protein of the present invention in the present invention in prevention and/or treatment and/or adjuvant therapy and / Or use in diagnosing related tumors or preparing drugs for preventing and/or treating and/or adjuvant treatment and/or diagnosing related tumors.
  • the tumor is preferably a CD47-expressing tumor, preferably cancer, such as malignant hematological tumor or solid tumor, more preferably lymphoma, colon cancer or breast cancer, more preferably non-Hodgkin’s lymphoma, and still more Preferred are B-cell lymphoma cells.
  • cancer such as malignant hematological tumor or solid tumor, more preferably lymphoma, colon cancer or breast cancer, more preferably non-Hodgkin’s lymphoma, and still more Preferred are B-cell lymphoma cells.
  • the drug is in a form suitable for injection, preferably a form suitable for administration by subcutaneous injection, intradermal injection, intravenous injection, intramuscular injection or intralesional injection.
  • the term "antigen binding region” means a protein or part of a protein that specifically binds to a specified antigen.
  • the antigen binding region usually includes one or more "complementarity-determining regions” ("CDR").
  • CDR complementarity-determining regions
  • Certain antigen binding regions also include one or more "fragment regions” (“FR”).
  • CDR is an amino acid sequence that contributes to antigen binding specificity and affinity.
  • antibody refers to an intact immunoglobulin of any isotype or an antigen-binding fragment thereof that can compete with an intact antibody for specific binding to a target antigen, and includes, for example, a chimeric antibody, Humanized antibodies, fully humanized antibodies and bispecific antibodies or antigen-binding fragments thereof.
  • antibodies are types of antigen binding proteins. Intact antibodies usually contain at least two full-length heavy chains and two full-length light chains, but in some cases, may include fewer chains, such as antibodies naturally occurring in camelids that may contain only heavy chains.
  • the antibody or antigen-binding fragment thereof may be derived from only a single source, or may be "chimeric", that is, different parts of the antibody may be derived from two different sources as described further below.
  • Antibodies or antigen-binding fragments thereof can be produced in hybridomas by recombinant DNA technology, or by enzymatic or chemical cleavage of whole antibodies.
  • the term “antibody” or “antigen-binding fragment” (or “fragment” for short) of an “immunoglobulin chain (heavy or light chain)” includes the absence of at least some of the full-length antibody chain The amino acid in but the part of the antibody that can specifically bind to the antigen (this part is obtained or synthesized anyway).
  • Such fragments are biologically active because they specifically bind to the target antigen and can compete with other antibodies or antigen-binding fragments thereof for specific binding to a given epitope.
  • such fragments will retain at least one CDR present in the full-length light or heavy chain of the antibody, and in some embodiments will comprise a single heavy chain and/or light chain or a portion thereof.
  • Immune functional immunoglobulin fragments include, but are not limited to Fab, Fab', F(ab') 2 , Fab/c, dAb, Fv, domain antibodies and single chain antibodies, and can be derived from any mammalian source, including But not limited to humans, mice, rats, camelids or rabbits.
  • the functional portion of the antibody disclosed herein can be covalently bound to a second protein or small molecule to generate a therapeutic agent directed to a specific target in the body, thereby having bifunctional therapeutic properties or having Prolonged serum half-life, such as fusion proteins.
  • antibody full-length chain As used in the present invention, the terms “antibody full-length chain”, “full-length antibody”, “intact antibody” and “whole antibody” are used interchangeably herein to refer to such
  • the antibody has a structure substantially similar to the structure of a natural antibody or a heavy chain with an Fc region as defined herein.
  • the term "light chain” includes full-length light chains and their fragments with sufficient variable region sequences to confer binding specificity. Domain comprises a full length light chain V domain C L L variable regions and constant regions. The variable domain of the light chain is at the amino terminus of the polypeptide.
  • the light chain includes kappa chain and lambda chain.
  • the term "heavy chain” includes the full-length heavy chain and its fragments with sufficient variable region sequence to confer binding specificity.
  • Full length heavy chain includes a variable region domain and V H domain C H1, C H2 C H3 3, and two constant region.
  • V H domain is at the amino terminus of a polypeptide, and the C H domain at the carboxy terminus, C H3 closest to the carboxy terminus of a polypeptide.
  • the heavy chain can have any isotype, including IgG (including IgG1, IgG2, IgG3, and IgG4 subtypes), IgA (including IgAl and IgA2 subtypes), IgM, and IgE.
  • Fab fragment consists of a light chain and CH1 and the variable region of a heavy chain.
  • the heavy chain of the Fab molecule cannot form a disulfide bond with another heavy chain molecule.
  • Fc region contains a fragment of the heavy chain C H2 and C H1 domains of the two antibodies comprises.
  • the two heavy chain fragments are held together by two or more disulfide bonds and by the hydrophobic interaction of the CH3 domain.
  • Fab 'fragment contains one light chain and one heavy chain portion (which contains the region between the V H and C H1 domain and also the C H1 domain and the C H2 domain ), so that an interchain disulfide bond can be formed between the two heavy chains of the two Fab' fragments to form F(ab') 2 molecules.
  • F (ab ') 2 fragment contains two light chains and two heavy chains containing a portion of the constant region between the C H2 and C H1 domain, so the two heavy Interchain disulfide bonds are formed between the chains.
  • the F(ab') 2 fragment thus consists of two Fab' fragments held together by the disulfide bond between the two heavy chains.
  • Fv region includes variable regions derived from heavy and light chains, but lacks constant regions.
  • Fd fragment means an antibody fragment composed of VH and CH1 domains (Ward et al., Nature 341:544-546 (1989)).
  • dAb dAb fragment (Ward et al., Nature 341: 544-546 (1989) ) by the V H domain.
  • Fab'-SH is the designation for Fab' herein, in which one or more cysteine residues of the constant domain carry a free thiol group.
  • Fab/c fragment is an antibody cleavage intermediate product formed by pepsin digestion of immunoglobulin. It has the advantages of both Fab and Fc regions, that is, it has strong diffusion ability and slow metabolism and clearance in vivo. It can maintain high affinity (Liu Jianjun, "Journal of Cellular and Molecular Immunology", 1989(4): 29-29).
  • single chain antibody is an Fv molecule in which the variable regions of the heavy chain and the light chain are connected by a flexible linker to form a single polypeptide chain (which forms the antigen binding region) (see, for example, Bird et al. Human, Science. 242: 423-426 (1988) and Huston et al., Proc. Natl. Acad. Sci. USA. 90: 5879-5883 (1988)).
  • Single-chain antibodies are described in detail in International Patent Application Publication No. WO 88/01649 and U.S. Patent 4,946,778 and U.S. Patent 5,260,203 (the disclosures of the International Patent Application Publication No. and U.S. Patent No. are incorporated by reference).
  • domain antibody is an immunologically functional immunoglobulin fragment containing only the variable region of the heavy chain or the variable region of the light chain, including multivalent domain antibodies or bivalent domains antibody.
  • two or more VH regions are covalently linked by a peptide linker to generate multivalent domain antibodies (especially bivalent domain antibodies).
  • the two VH regions of a bivalent domain antibody can target the same or different antigens.
  • bivalent antigen binding protein or “bivalent antibody” includes two antigen binding sites. In some cases, the two binding sites have the same antigen specificity. Bivalent antibodies can be bispecific.
  • multispecific antigen binding protein or “multispecific antibody” is an antigen binding protein or antibody that targets more than one antigen or epitope.
  • bispecific As used in the present invention, the terms "bispecific", “dual specific” or “bifunctional” antigen binding protein or antibody are hybrid antigen binding proteins or antibodies each having two different antigen binding sites.
  • a bispecific antibody is a multispecific antigen binding protein or multispecific antibody, and can be produced by a variety of methods, including, but not limited to, the fusion of hybridomas or the linking of Fab' fragments. See, for example, Songsivilai and Lachmann, 1990, Clin. Exp. Immunol. 79: 315-321; Kostelny et al., 1992, J. Immunol. 148: 1547-1553.
  • the two binding sites of a bispecific antigen binding protein or antibody will bind to two different epitopes that are present on the same or different protein targets.
  • the terms "monoclonal antibody” and “monoclonal antibody” refer to an antibody or a fragment of an antibody from a group of highly homologous antibody molecules, that is, in addition to natural mutations that may occur spontaneously , A group of identical antibody molecules.
  • the monoclonal antibody has high specificity for a single epitope on the antigen.
  • Polyclonal antibodies are relative to monoclonal antibodies, which usually contain at least two or more different antibodies, and these different antibodies usually recognize different epitopes on the antigen.
  • Monoclonal antibodies can usually be obtained using the hybridoma technology first reported by Kohler et al. (Nature, 256:495, 1975), but can also be obtained using recombinant DNA technology (for example, see U.S.P 4,816,567).
  • humanized antibody means that all or part of the CDR region of a human immunoglobulin (acceptor antibody) is replaced by a CDR region of a non-human antibody (donor antibody)
  • the obtained antibody or antibody fragment wherein the donor antibody may be a non-human (e.g., mouse, rat or rabbit) antibody with the expected specificity, affinity or reactivity.
  • some amino acid residues in the framework region (FR) of the acceptor antibody can also be replaced by corresponding non-human antibody amino acid residues, or by other antibody amino acid residues, to further improve or optimize the performance of the antibody.
  • epitope refers to a site on an antigen that is specifically bound by an immunoglobulin or antibody.
  • Epitope is also called “antigenic determinant” in the art.
  • Epitopes or antigenic determinants usually consist of chemically active surface groups of molecules such as amino acids or carbohydrates or sugar side chains and usually have specific three-dimensional structural characteristics as well as specific charge characteristics.
  • an epitope usually includes at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 consecutive or non-contiguous amino acids in a unique spatial conformation, which can be "linear ⁇ " or “conformational”. See, for example, Epitope Mapping Protocols in Methods in Molecular Biology, Volume 66, G.E. Morris, Ed.
  • polypeptide or "protein” are used interchangeably herein to refer to a polymer of amino acid residues.
  • the term is also used for amino acid polymers in which one or more amino acid residues are analogs or mimetics of the corresponding naturally occurring amino acid, as well as for naturally occurring amino acid polymers.
  • the term may also include amino acid polymers that have been modified or phosphorylated, for example, by adding carbohydrate residues to form glycoproteins.
  • Polypeptides and proteins can be produced by naturally occurring cells and non-recombinant cells; or they are produced by genetic engineering or recombinant cells, and contain molecules with the amino acid sequence of a natural protein, or deletions, additions, and additions of one or more amino acids of the natural sequence. / Or substituted molecules.
  • polypeptide and protein specifically include antibodies, such as anti-human CD47 antibodies (also known as CD47 antibodies), CD47 binding proteins, or variants thereof, such as having a deletion of one or more amino acids , Added and/or substituted antibodies or sequences.
  • antibodies such as anti-human CD47 antibodies (also known as CD47 antibodies), CD47 binding proteins, or variants thereof, such as having a deletion of one or more amino acids , Added and/or substituted antibodies or sequences.
  • polypeptide fragment refers to a polypeptide having amino-terminal deletions, carboxy-terminal deletions and/or internal deletions compared to full-length proteins. Such fragments may also contain modified amino acids compared to the full-length protein. In certain embodiments, the length of the fragment is about 5 to 500 amino acids. For example, the length of the fragment may be at least 5, 6, 8, 10, 14, 20, 50, 70, 100, 110, 150, 200, 250, 300, 350, 400, or 450 amino acids in length.
  • Useful polypeptide fragments include immunologically functional fragments of antibodies, including binding domains. In the case of human CD47 antibodies, useful fragments include but are not limited to CDR regions, variable domains of heavy or light chains, parts of antibody chains, or variable domains that happen to include 2 CDRs, and the like.
  • a “derivative" of a polypeptide is a polypeptide that is chemically modified by conjugation of another chemical moiety (e.g., antigen binding protein or antibody) in a manner different from insertion, deletion or substitution variants, e.g., PEG-conjugated Peptides.
  • another chemical moiety e.g., antigen binding protein or antibody
  • the terms “isolated” or “isolated” refer to those obtained from the natural state by artificial means. If a certain "isolated” substance or component appears in nature, it may be that the natural environment in which it is located has changed, or the substance has been isolated from the natural environment, or both. For example, a certain unisolated polynucleotide or polypeptide naturally exists in a living animal, and the same polynucleotide or polypeptide with high purity isolated from this natural state is called isolation. of.
  • isolation a certain unisolated polynucleotide or polypeptide naturally exists in a living animal, and the same polynucleotide or polypeptide with high purity isolated from this natural state is called isolation. of.
  • isolation polynucleotide or polypeptide with high purity isolated from this natural state is called isolation. of.
  • isolated does not exclude the mixing of artificial or synthetic materials, nor does it exclude the presence of other impure materials that do not affect the activity of the material.
  • the term "vector” refers to a nucleic acid delivery vehicle into which a polynucleotide can be inserted.
  • the vector can express the protein encoded by the inserted polynucleotide, the vector is called an expression vector.
  • the vector can be introduced into the host cell through transformation, transduction or transfection, so that the genetic material elements it carries can be expressed in the host cell.
  • Vectors are well known to those skilled in the art, including but not limited to: plasmids; phagemids; cosmids; artificial chromosomes, such as yeast artificial chromosomes (YAC), bacterial artificial chromosomes (BAC) or P1 derived artificial chromosomes (PAC) ; Phages such as lambda phage or M13 phage and animal viruses.
  • Animal viruses that can be used as vectors include, but are not limited to, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpes viruses (such as herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, and papillary viruses.
  • Polyoma vacuole virus (such as SV40).
  • a vector may contain a variety of elements for controlling expression, including but not limited to promoter sequences, transcription initiation sequences, enhancer sequences, selection elements and reporter genes.
  • the vector may also contain an origin of replication site.
  • the term "host cell” refers to a cell that can be used to introduce a vector, which includes, but is not limited to, prokaryotic cells such as Escherichia coli or Bacillus subtilis, and fungi such as yeast cells or Aspergillus Cells, such as insect cells such as S2 Drosophila cells or Sf9, or animal cells such as fibroblasts, CHO cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK 293 cells or human cells.
  • prokaryotic cells such as Escherichia coli or Bacillus subtilis
  • fungi such as yeast cells or Aspergillus Cells
  • insect cells such as S2 Drosophila cells or Sf9
  • animal cells such as fibroblasts, CHO cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK 293 cells or human cells.
  • the term "specific binding” refers to a non-random binding reaction between two molecules, such as the reaction between an antibody and the antigen to which it is directed.
  • an antibody that specifically binds to a certain antigen means that the antibody has a concentration of less than about 10 -5 M, for example, less than about 10 -6 M, 10 -7 M, The affinity (K D ) of 10 -8 M, 10 -9 M, or 10 -10 M or less binds to the antigen.
  • K D refers to the dissociation equilibrium constant of a specific antibody-antigen interaction, which is used to describe the binding affinity between the antibody and the antigen.
  • K D is the dissociation equilibrium constant. In antibody drug research, it is a parameter that characterizes the affinity between the tested antibody and the target antigen molecule.
  • the binding rate constant the rate at which the antigen-antibody complex is formed, the smaller the kon, the faster the binding of the antibody to the antigen;
  • kdis, the dissociation rate constant the rate at which the antibody dissociates from the antigen-antibody complex, the smaller the kdis That is, the slower the antibody detaches from the antigen, the stronger the binding of the antibody to the antigen.
  • the antibody has a dissociation equilibrium constant (K D ) less than about 10 -5 M, for example, less than about 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M, or 10 -10 M or less Bound antigen (for example, L1 protein), for example, as measured in a BIACORE instrument or a Fortebio molecular interaction instrument using surface plasmon resonance (SPR).
  • K D dissociation equilibrium constant
  • the terms “monoclonal antibody” and “monoclonal antibody” have the same meaning and can be used interchangeably; the terms “polyclonal antibody” and “polyclonal antibody” have the same meaning and can be used interchangeably;
  • the terms “polypeptide” and “protein” have the same meaning and are used interchangeably.
  • amino acids are usually represented by one-letter and three-letter abbreviations well known in the art. For example, alanine can be represented by A or Ala.
  • hybridomas As used in the present invention, the terms “hybridoma” and “hybridoma cell line” are used interchangeably, and when the terms “hybridoma” and “hybridoma cell line” are referred to, they also include subgroups of hybridomas. Clones and progeny cells.
  • percent sequence identity As used herein, the terms “percent sequence identity” and “percent sequence homology” are used interchangeably.
  • the terms “similarity” or “sequence similarity” and “identity” refer to the relationship between the sequences of two or more protein or polypeptide molecules, as determined by alignment and comparison of sequences .
  • Perfect identity means the percentage of identical residues between amino acids in the molecules being compared, and can be calculated based on the size of the smallest molecule to be compared. In order to perform these calculations, a specific mathematical model or computer program (ie, “algorithm”) must be used to resolve the gaps in the alignment (if any).
  • algorithm ie, “algorithm”
  • the default gap weights provided by the programs are used for optimal alignment, and a total of at least 70%, 75% or 80% sequence identity, at least 90% or 95% sequence identity, and at least 97%, 98%, or 99% sequence identity.
  • residues that are not identical differ by conservative amino acid substitutions.
  • a "conservative amino acid substitution” is a substitution in which an amino acid residue is replaced with another amino acid residue having a side chain R group that possesses similar chemical properties (eg, charge or being aqueous). Generally, conservative amino acid substitutions will not substantially change the functional properties of the protein.
  • the percent sequence identity can be adjusted up to correct for the conservative nature of the substitutions.
  • the method for making this adjustment is well known to those skilled in the art. See, for example, Pearson, Methods Mol. Biol. 243: 307-31 (1994).
  • amino acid groups having side chains with similar chemical properties include 1) aliphatic hydroxyl side chains: glycine, alanine, valine, leucine, and isoleucine: 2) aliphatic hydroxyl side chains: serine And Threonine: 3) Amide-containing side chain: Asparagine and Glutamine: 4) Aromatic side chain: Phenylalanine, Tyrosine and Tryptophan: 5) Basic side chain: Lysine , Arginine and histidine: 6) acidic side chains: aspartic acid and glutamic acid; and 7) sulfur-containing side chains: cysteine and methionine.
  • the conservative amino acid substitution group is valine-leucine-isoleucine-glycine-alanine, phenylalanine-tyrosine, threonine-serine, lysine-arginine, glutamine Amino acid-aspartic acid and asparagine-glutamine
  • a conservative substitution is any positive value in the PAM250 log-likelihood matrix (PAM250 log-likelihood matrix) disclosed in Gonnet et al., Science 256:1443-45 (1992) (incorporated herein by reference) Variety.
  • a "moderately conservative” substitution is any change that has a non-negative value in the PAM250 log-likelihood matrix.
  • Sequence analysis software is usually used to measure the sequence identity of polypeptides. Protein analysis software uses measures of similarity assigned to different substitutions, deletions, and other modifications (including conservative amino acid substitutions) to match sequences. For example, GCG includes programs such as "Gap” and "Bestfit", which (using the default parameters specified by the program) can be used to determine closely related polypeptides (such as homologous polypeptides from different biological species) or wild-type proteins. Sequence homology or sequence identity between its mutant protein. See, for example, GCG Version 6.1 (University of Wisconsin, WI). You can also use the default or recommended parameters to compare peptide sequences using FASTA.
  • FASTA for example, FASTA2 and FASTA3 provides alignment and percent sequence identity (Pearson , Methods Enzymol. 183: 63-98 (1990): Pearson, Methods Mol. Biol. 132: 185-219 (2000)).
  • Another preferred algorithm is the computer program BLAST, in particular blastp or tblastn (using the default parameters provided by the program). See, for example, Altschul et al., Mol. Biol. 215: 403-410 (1990): Altschul et al., Nucleic Acids Res. 25: 3389-402 (1997).
  • the present invention has, for example, the following advantages:
  • the anti-CD47 monoclonal antibody of the present invention can effectively block the binding of SIRP ⁇ and CD47 by specifically binding to CD47, thereby promoting the phagocytosis of tumor cells by macrophages.
  • the antibody of the present invention e.g. 6F7H1L1
  • Figure 1 The binding activity test results of 6F7 H1L1 (hG4) and human CD47 IgV TEV-His.
  • FIG. 1 Results of the detection of binding activity between 6F7 H1L1 (G1M) and human CD47 IgV TEV-His.
  • 6F7 H1L1 hG1DM
  • 6F7 H1L1 G1M
  • FIG. 3 The activity test results of 6F7 H1L1 (hG4) and human SIRP ⁇ ECD-hFc-Biotin in binding to human CD47 IgV TEV-His.
  • FIG. 4 Activity test results of 6F7H1L1 (G1M) and human SIRP ⁇ ECD-hFc-Biotin in binding to human CD47 IgV TEV-His.
  • 6F7 H1L1 hG1DM
  • 6F7 H1L1 G1M
  • Fig. 5 The result of the detection of the affinity constant between the mouse antibody 6F7 and human CD47.
  • Figure 7 The result of the detection of the affinity constant between Hu5F9-G4 and human CD47.
  • FIG. 8 6F7 H1L1 (G1M) and human RBC binding curve (FACS).
  • Figure 9 6F7 H1L1 (G1M) binding activity (FACS) to tumor cell Raji.
  • FIG. 10 6F7 H1L1 (G1M) competes with SIRP to bind LOVO activity detection (FACS).
  • FIG. 11 The agglutination effect of 6F7 H1L1 (G1M) antibody on human red blood cells.
  • Figure 12 The binding curve (FACS) of 6F7 H1L1 (hG4) and human RBC.
  • FIG. 13 The binding activity (FACS) of 6F7 H1L1 (hG4) with tumor cell Raji.
  • FIG. 14 Competitive binding activity (FACS) of 6F7 H1L1 (hG4) competing with SIRP for binding to tumor cells Raji.
  • Figure 15 The binding curve (FACS) of 6F7 H1L1 (hG4) and tumor cell LOVO.
  • FIG. 17 Agglutination of anti-CD47 antibody on human red blood cells.
  • FIG. 18 The therapeutic effect of 6F7 H1L1 (hG4) on MDA-MB-231 subcutaneous xenograft tumor.
  • FIG. 19 Changes in hemoglobin concentration of 6F7 H1L1 (hG4) and Hu5F9-G4 cynomolgus monkeys after a single dose.
  • FIG. 20 Hematocrit changes in 6F7 H1L1 (hG4) and Hu5F9-G4 cynomolgus monkeys after a single dose.
  • hybridoma cell line LT012 which was deposited in the China Type Culture Collection (CCTCC) on June 21, 2018, with the deposit number CCTCC NO: C2018135, and the deposit address is Wuhan University, Wuhan, China, Zip Code: 430072.
  • the BALB/C mice used were purchased from Guangdong Medical Experimental Animal Center.
  • the control antibody drug used was Hu5F9-G4 (synthesized by Zhongshan Kangfang Biomedicine Co., Ltd., prepared by Forty Seven, Inc.'s CD47 antibody Hu5F9-G4 sequence, that is, SEQ ID NO: 37 of US20150183874 as the heavy chain variable region , SEQ ID NO: 42 is used as the light chain variable region, and the Ig gamma-4 chain constant region (GenbankID: P01861.1)).
  • the anti-CD47 antibody used in the hybridoma cell line 6F7 is CD47 IgV TEV-His (including GenbankID: NP 942088.1 Position: 19-141 human CD47 mature peptide and TEV (amino acid sequence is ENLYFQG, SEQ ID NO: 74)-his
  • the tagged fusion protein synthesized by Zhongshan Kangfang Biomedical Co., Ltd. and 3T3-CD47 cells (NIH/3T3, manufacturer: ATCC, article number: CRL-1658, transfected with the above-mentioned human CD47 mature peptide on the basis of NIH/3T3) Cells to construct a stable expression line of 3T3-CD47).
  • the spleen cells of the immunized mice were fused with mouse myeloma cells to make hybridoma cells.
  • CD47 IgV TEV-His and 3T3-CD47 cells were used as antigens.
  • the hybridoma cells were screened by indirect ELISA method to obtain the secretory cells. Hybridoma cells with antibodies that specifically bind to CD47.
  • hybridoma cells screened by ELISA were screened by competitive ELISA to secrete human SIRP ⁇ ECD-hFc-Biotin (wherein SIRP ⁇ ECD represents the extracellular region of SIRP ⁇ , protein GenBank accession number: NP_542970.1 position 31-373; hFc It is a human IgG Fc purification tag, specifically Ig gamma-1 chain C region, GenbankID: P01857 position 114-330) hybridoma cell line that competes with the monoclonal antibody binding to human CD47 IgV TEV-His, and obtains stable by limiting dilution method Hybridoma cell line.
  • the above hybridoma cell line was named hybridoma cell line LT012, and the monoclonal antibody secreted by it was named 6F7.
  • the hybridoma cell line LT012 (CD47-6F7), which was deposited in the China Center for Type Culture Collection (CCTCC) on June 21, 2018, the deposit number is CCTCC NO: C2018135, and the deposit address is Wuhan, China, Wuhan University, Zip Code : 430072.
  • CD medium Cosmetic Defined Medium
  • penicillin streptomycin in 5% CO 2 , 37°C cell incubator Culture
  • the cell culture supernatant was collected, and purified by high-speed centrifugation, vacuum filtration with a microporous membrane, and HiTrap protein A HP column to prepare antibody 6F7.
  • the mRNA was extracted from the LT012 cell line cultured in Example 1 according to the method of the cultured cell bacterial total RNA extraction kit (Tiangen, article number DP430).
  • the PCR amplification product is directly subjected to TA cloning, and the specific operation refers to the pEASY-T1 Cloning Kit (Transgen CT101) kit manual.
  • the TA cloned product was directly sequenced, and the sequencing results are as follows:
  • the nucleic acid sequence of the heavy chain variable region is shown in SEQ ID NO: 1, and the length is 351 bp.
  • the encoded amino acid sequence is shown in SEQ ID NO: 2 and the length is 117aa.
  • the sequence of heavy chain CDR1 is shown in SEQ ID NO: 5
  • the sequence of heavy chain CDR2 is shown in SEQ ID NO: 6
  • the heavy chain CDR3 is shown in SEQ ID NO: 6.
  • the sequence of is shown in SEQ ID NO: 7.
  • the nucleic acid sequence of the light chain variable region is shown in SEQ ID NO: 3, and the length is 321 bp.
  • the encoded amino acid sequence is shown in SEQ ID NO: 4, and the length is 107aa.
  • the light chain CDR1 sequence is shown in SEQ ID NO: 8
  • the light chain CDR2 sequence is shown in SEQ ID NO: 9
  • the light chain CDR3 is shown in SEQ ID NO: 9
  • the sequence of is shown in SEQ ID NO: 10.
  • Example 3 Anti-human CD47 humanized antibody 6F7 H1L1 (hG4), 6F7 H2L2 (hG4) and 6F7 H3L3 (hG4) light chain and heavy chain design and preparation
  • the designed variable region sequence is as follows:
  • the nucleic acid sequence of the heavy chain variable region is shown in SEQ ID NO: 11, and the length is 351 bp.
  • the encoded amino acid sequence is shown in SEQ ID NO: 12, and the length is 117aa.
  • the sequence of the heavy chain CDR1 is shown in SEQ ID NO: 5
  • the sequence of the heavy chain CDR2 is shown in SEQ ID NO: 6
  • the heavy chain CDR3 is shown in SEQ ID NO: 6.
  • the sequence of is shown in SEQ ID NO: 7.
  • the nucleic acid sequence of the light chain variable region is shown in SEQ ID NO: 13, and the length is 321 bp.
  • the encoded amino acid sequence is shown in SEQ ID NO: 14, and the length is 107aa.
  • the light chain CDR1 sequence is shown in SEQ ID NO: 8
  • the light chain CDR2 sequence is shown in SEQ ID NO: 9
  • the light chain CDR3 is shown in SEQ ID NO: 9.
  • the sequence of is shown in SEQ ID NO: 10.
  • the nucleic acid sequence of the heavy chain variable region is shown in SEQ ID NO: 15, and the length is 351 bp.
  • the encoded amino acid sequence is shown in SEQ ID NO: 16, and the length is 117aa.
  • the sequence of heavy chain CDR1 is shown in SEQ ID NO: 5
  • the sequence of heavy chain CDR2 is shown in SEQ ID NO: 6
  • the heavy chain CDR3 is shown in SEQ ID NO: 6.
  • the sequence of is shown in SEQ ID NO: 7.
  • the nucleic acid sequence of the light chain variable region is shown in SEQ ID NO: 17, and the length is 321 bp.
  • the encoded amino acid sequence is shown in SEQ ID NO: 18, and the length is 107aa.
  • the light chain CDR1 sequence is shown in SEQ ID NO: 8
  • the light chain CDR2 sequence is shown in SEQ ID NO: 9
  • the light chain CDR3 is shown in SEQ ID NO: 9.
  • the sequence of is shown in SEQ ID NO: 10.
  • the nucleic acid sequence of the heavy chain variable region is shown in SEQ ID NO: 19, and the length is 351 bp.
  • the encoded amino acid sequence is shown in SEQ ID NO: 20, and the length is 117aa.
  • the sequence of heavy chain CDR1 is shown in SEQ ID NO: 5
  • the sequence of heavy chain CDR2 is shown in SEQ ID NO: 6
  • the heavy chain CDR3 is shown in SEQ ID NO: 6.
  • the sequence of is shown in SEQ ID NO: 7.
  • the nucleic acid sequence of the light chain variable region is shown in SEQ ID NO: 21, and the length is 321 bp.
  • the encoded amino acid sequence is shown in SEQ ID NO: 22 and the length is 107aa.
  • the light chain CDR1 sequence is shown in SEQ ID NO: 8
  • the light chain CDR2 sequence is shown in SEQ ID NO: 9
  • the light chain CDR3 is shown in SEQ ID NO: 9
  • the sequence of is shown in SEQ ID NO: 10.
  • the heavy chain constant regions all use Ig gamma-4 chain C region, ACCESSION: P01861.1; the light chain constant regions all use Ig kappa chain C region, ACCESSION: P01834.
  • the 6F7H1L1 (hG4) heavy chain cDNA and light chain cDNA, 6F7H2L2 (hG4) heavy chain cDNA and light chain cDNA, and 6F7H3L3 (hG4) heavy chain cDNA and light chain cDNA were cloned into pUC57simple (GenScript In the vector provided by the company, pUC57simple-6F7H1, pUC57simple-6F7L1; pUC57simple-6F7H2, pUC57simple-6F7L2, pUC57simple-6F7H3 and pUC57simple-6F7L3 were obtained respectively.
  • the recombinant plasmid design genes containing the corresponding light and heavy chains (pcDNA3.1-6F7H1/pcDNA3.1-6F7L1, pcDNA3.1-6F7H2/pcDNA3.1-6F7L2, and pcDNA3.1-6F7H3/pcDNA3.1- 6F7L3)
  • the culture broth was collected for purification.
  • the sequencing verification is correct, prepare the endotoxin-free expression plasmid and transiently transfect the plasmid into HEK293 cells for antibody expression.
  • the cell culture fluid is collected, and the protein A column (MabSelect SURE (GE)) is used for affinity purification to obtain humans. Sourced antibody.
  • variable region sequences of antibodies 6F7H1L1, 6F7 H2L2 and 6F7 H3L3 were obtained (antibody constant region sequence, from NCBI In the database, the heavy chain constant region is Ig gamma-1 chain C region, ACCESSION: P01857; the light chain constant region is Ig kappa chain C region, ACCESSION: P01834), in order to distinguish it from the humanized antibody in Example 3 above
  • the above-mentioned humanized antibodies were named 6F7H1L1 (G1), 6F7H2L2 (G1) and 6F7H3L3 (G1), respectively.
  • the humanized antibodies 6F7H1L1(G1), 6F7H2L2(G1) and 6F7H3L3(G1) designed in this example have the same variable region sequences as 6F7H1L1(hG4), 6F7H2L2(hG4) and 6F7H3L3(hG4) in Example 3. ) Has the same variable region sequence.
  • the heavy chain constant region uses Ig gamma-1 chain C region, ACCESSION: P01857; the light chain constant region uses Ig kappa chain C region, ACCESSION: P01834.
  • 6F7H1L1 heavy chain cDNA and light chain cDNA, 6F7H2L2 heavy chain cDNA and light chain cDNA, and 6F7H3L3 heavy chain cDNA and light chain cDNA were cloned into pUC57simple (provided by GenScript) vector to obtain pUC57simple.
  • the recombinant plasmid design genes containing the corresponding light and heavy chains (pcDNA3.1-6F7H1/pcDNA3.1-6F7L1, pcDNA3.1-6F7H2/pcDNA3.1-6F7L2, and pcDNA3.1-6F7H3/pcDNA3.1- 6F7L3)
  • the culture broth was collected for purification.
  • the sequencing verification is correct, prepare the endotoxin-free expression plasmid and transiently transfect the plasmid into HEK293 cells for antibody expression.
  • the cell culture fluid is collected, and the protein A column (MabSelect SURE (GE)) is used for affinity purification to obtain humans. Sourced antibody.
  • 6F7H1L1 (G1), 6F7H2L2 (G1) and 6F7 H3L3 (G1) the inventor introduced a leucine to alanine point mutation (L234A) at position 234 of its heavy chain hinge region, A leucine to alanine point mutation (L235A) was introduced at position 235, and new humanized antibodies were obtained, and they were named 6F7H1L1 (G1M), 6F7H2L2 (G1M) and 6F7 H3L3 (G1M).
  • Example 5 ELISA method to detect the binding activity of antibody and antigen
  • test results are shown in Figure 3.
  • the OD value of each dose is shown in Table 3.
  • the curve simulates the binding efficiency of the antibody to obtain the binding EC50 (Table 3).
  • 6F7 H1L1 (hG4) can effectively block the binding of the antigen human CD47 IgV TEV-His and its receptor human SIRP ⁇ ECD-hFc-Biotin, and the blocking efficiency is dose-dependent.
  • the blocking EC50 of 6F7 H1L1 (hG4) is 0.194nM, the blocking activity is the same as Hu5F9-G4.
  • test results are shown in Figure 4.
  • the OD value of each dose is shown in Table 4.
  • the curve simulates the binding efficiency of the antibody to obtain the binding EC50 (Table 4).
  • 6F7 H1L1 (G1M) can effectively block the binding of the antigen human CD47 IgV TEV-His and its receptor human SIRP ⁇ ECD-hFc-Biotin, and the blocking efficiency is dose-dependent.
  • the blocking EC50 of 6F7 H1L1 (G1M) is 0.274nM, the blocking activity is equivalent to Hu5F9-G4.
  • the Fortebio molecular interaction instrument (Forteio, model: QKe) was used to determine the kinetic parameters of the binding of the mouse antibody 6F7 to the antigen human CD47 IgV TEV-His.
  • EDC/NHS Use EDC/NHS to activate the AR2G sensor (Forteio, article number: 18-5092), and fix the antibody to the activated AR2G sensor by amino coupling.
  • the sensor is equilibrated in PBST for 300s, and the antigen fixed on the sensor is combined with the antibody.
  • the antigen concentration is 3.125-100nM (two-fold gradient dilution), the binding time is 420s, and the antigen antibody dissociates in PBST for 600s.
  • the results show that the results are shown in Table 5 and Figure 5.
  • the affinity constants of mouse antibodies 6F7 and Hu5F9-G4 and human CD47 IgV TEV-His are 6.52E-10M and 6.38E-10M, respectively.
  • the results of the two affinity constants are equivalent. . It is suggested that the CDR region of 6F7 has the same ability to bind to CD47 as Hu5F9-G4, and both have strong binding ability.
  • the Biacore molecular interaction instrument (Forteio, model: QKe) was used to detect the affinity constant of the antibody 6F7 H1L1 (hG4) and human CD47 IgV TEV-His.
  • the buffer is PBST, and human CD47 IgV-TEV-His is immobilized on the surface of the CM5 chip by amino coupling, and the immobilized signal value is 171.6RU.
  • the antibody binds to human CD47, the antibody concentration is 0.78-12.5nM (two-fold dilution), the flow rate is 30 ⁇ L/min, the binding time is 120s, and the dissociation time is 300s.
  • the chip is regenerated with 3M MgCl 2 at a flow rate of 30 ⁇ L/min and a time of 30 s.
  • the data was analyzed by a 1:1 model to get the affinity constant.
  • Biacore Control 2.0 software was used for data acquisition, and Biacore T200 Evaluation 2.0 software was used for data analysis.
  • the test results of the affinity constants of 6F7 H1L1 (hG4) and Hu5F9-G4 (as a control antibody) with human CD47 IgV TEV-His are shown in Table 6, and the test results are shown in Figs. 6 and 7.
  • the FACS method detects the combination of 6F7 H1L1 (G1M) and normal RBC
  • Figure 8 shows the results of 6F7 H1L1 (G1M) binding to CD47 on the surface of normal human RBC cell membranes.
  • the results showed that 6F7 H1L1 (G1M) and Hu5F9-G4, a marketed drug with the same target, can specifically bind to CD47 on the surface of normal human RBC cell membranes, and their binding EC50 is 0.077nM and 0.057nM, respectively, and their binding activities are equivalent.
  • Figure 9 shows the results of the binding activity of 6F7 H1L1 (G1M) and Raji.
  • the results of the binding test show that 6F7 H1L1 (G1M) and Hu5F9-G4 can specifically bind to CD47 on the surface of Raji cell membranes, and their binding EC50 is 0.013nM and 0.012nM, respectively, and their binding activities are equivalent.
  • a blank control 100 ⁇ L 1% PBSA plus Cells
  • isotype control human IgG
  • 6F7 H1L1 competes with SIRP for binding LOVO activity detection.
  • the results are shown in Figure 10.
  • both 6F7 H1L1 (G1M) and Hu5F9-G4 can compete with SIRP to bind to CD47 on the LOVO membrane surface, thereby blocking the binding of SIRP and CD47.
  • the competitive binding EC50 is 0.16nM and 0.24nM, respectively, and the binding activity of both quite.
  • Preparation of normal human blood RBC Separate human blood PBMC according to the separation solution Ficoll-Paque Plus reagent instructions, and use the red blood cells at the bottom of the precipitation for this experiment; dilute the red blood cells with PBS to make the red blood cell concentration 1*10 7 /mL to obtain the red blood cell suspension Add the red blood cell suspension to the round bottom 96-well plate, add the corresponding concentration of positive antibody, add 0.1g/mL Dextran T500 for the control, add the corresponding hIgG or PBS for the negative control, and incubate at 37 degrees for 4 hours; observe the red blood cells Agglutination phenomenon and take pictures.
  • 6F7 H1L1 (G1M) The effect of 6F7 H1L1 (G1M) on the agglutination of normal human erythrocytes is shown in Figure 11.
  • 6F7 H1L1 (G1M) and the control antibody Hu5F9-G4 have no effect on red blood cell agglutination when the antibody concentration is lower than 20 ⁇ g/mL, but when the antibody concentration is higher than 20 ⁇ g/mL, Hu5F9-G4 can see obvious It promotes agglutination of red blood cells, but 6F7 H1L1(G1M) still has no effect on red blood cell agglutination.
  • FACS method detects the combination of 6F7 H1L1 (hG4) and normal RBC
  • Raji cells in log phase were routinely collected and centrifuged to wash. Resuspend the cell pellet in 1% PBSA, count the number of cells and their viability; adjust the cell concentration to an appropriate range with 1% PBSA, and transfer the cells to 1.5 mL centrifuge tubes in groups, each with 500 ⁇ L of a total of 300,000 cells, centrifuge at 5600 rpm for 5 minutes, Discard the supernatant; add the antibody after serial dilution (final concentration from high to low: 1, 0.3, 0.1, 0.01, 0.001, 0.0001 nM), and set a blank control (100 ⁇ L 1% PBSA plus cells) and isotype control ( Human IgG), incubated on ice for 30 min.
  • a blank control 100 ⁇ L 1% PBSA plus cells
  • isotype control Human IgG
  • Collect LOVO cells in log phase (Cell Center, Chinese Academy of Sciences, number: bio-73085), centrifuge and wash, resuspend the cell pellet in 500 ⁇ L 1% PBSA, count the number of cells and viability, press 3.0*10 5 cells/500 ⁇ L/tube to transfer the cells Transfer to a 1.5 mL centrifuge tube; centrifuge at 5600 rpm for 5 minutes to discard the supernatant; add the corresponding antibodies in gradient dilutions, 100 ⁇ L per tube according to the experimental design, and design a blank (PBSA+ cells) and isotype control group (human IgG, whose heavy chain sequence is SEQ ID NO: 72, the light chain sequence is SEQ ID NO: 73), incubate on ice for 1 hour; then, add 500 ⁇ L 1% PBSA, centrifuge at 5600 rpm for 5 minutes, and remove the supernatant; add 100 ⁇ L FITC goat anti-human IgG (1 : 500), mix and incuba
  • 6F7 H1L1 (hG4) and tumor cell LOVO are shown in Figure 15 and Table 10.
  • 6F7 H1L1 (hG4) and Hu5F9-G4 can specifically bind to CD47 on the surface of LOVO cell membrane, and their binding EC50 is 0.02nM and 0.06nM, respectively.
  • 6F7 H1L1(hG4) is slightly better than Hu5F9-G4.
  • the experimental procedure was the same as in Example 3, except that Raji cells were replaced with LOVO cells.
  • Preparation of normal human blood RBC Separate human blood PBMC according to the separation solution Ficoll-Paque_Plus (GE, article number: 17-1440-02) reagent instructions, and use the red blood cells at the bottom of the precipitation for this experiment; dilute the red blood cells with PBS to make the red blood cell concentration 1*10 7 /mL to obtain a red blood cell suspension; add the red blood cell suspension to a round-bottom 96-well plate, add the corresponding concentration of positive antibody, add 0.1g/mL Dextran T500 to the control, and add the corresponding human IgG1 (Kang Fang Biology) or PBS, placed at 37 degrees Celsius for 4 hours; observe the phenomenon of red blood cell agglutination and take pictures.
  • Ficoll-Paque_Plus GE, article number: 17-1440-02
  • Figure 17 shows the effect of 6F7H1L1 (hG4) on normal human erythrocyte agglutination.
  • 6F7H1L1 (hG4) did not cause erythrocyte agglutination at all test concentrations, and when the concentration of the control antibody Hu5F9-G4 was lower than 3.3 ⁇ g/mL, it did not cause erythrocyte agglutination.
  • concentration is greater than or equal, 10 ⁇ g/mL, Hu5F9-G4 can see obvious red blood cell aggregation.
  • the in vivo activity of 6F7 H1L1 was studied by measuring the volume of human breast cancer cell MDA-MB-231 transplanted subcutaneously on SCID/beige mice after 6F7 H1L1 (hG4) administration.
  • the collected MDA-MB-231 (ATCC, article number: HTB-26) cells were inoculated subcutaneously into the right waist fossa of SCID/beige mice at 5 ⁇ 10 6 cells/mouse, and 40 mice were inoculated in total.
  • the tumor volume reached about 100-120mm 3 , the mice were divided into 5 groups according to the tumor volume.
  • Model group Hu5F9-G4 high-dose group, Hu5F9-G4 low-dose group, 6F7 H1L1 (hG4) high-dose group and 6F7 H1L1 (hG4) Low-dose group, high-dose group is 0.2mg/kg, low-dose group is 0.02mg/kg, the day of grouping is recorded as D0, respectively in D0, D3, D7, D10, D14, D17 Administration, 7 in each group.
  • the control antibody Hu5F9-G4 high-dose group and 6F7 H1L1(hG4) high-dose group can effectively inhibit the growth of MDA-MB-231 tumors (P ⁇ 0.01), and Hu5F9 -G4 and 6F7 H1L1 (hG4) have a dose-effect relationship for the inhibition of MDA-MB-231 tumor growth.
  • the control antibody Hu5F9-G4 high-dose group, 6F7 H1L1(hG4) high-dose group, 6F7 H1L1(hG4) low-dose group The TGI (%) were 67%, 63%, and 25% respectively.
  • the 6F7 H1L1(hG4) low-dose group had significantly better efficacy than Hu5F9-G4, and the high-dose was equivalent to 6F7 H1L1(hG4) high-dose
  • the efficacy is equivalent to the high dose of the control antibody, (P>0.05).
  • Example 11 Effect of single administration of 6F7 H1L1(hG4) and Hu5F9-G4 cynomolgus monkey on hemoglobin and hematocrit
  • cynomolgus monkeys were randomly divided into 2 groups according to body weight and sex, with 2 in each group, half male and female.
  • the blood analyzer detects hemoglobin and hematocrit.
  • HCDR1 GYTFTSYW (SEQ ID NO: 5)
  • HCDR2 IDPSDSET (SEQ ID NO: 6)
  • HCDR3 ARLYRWYFDV (SEQ ID NO: 7)
  • LCDR1 EIVGTY (SEQ ID NO: 8)
  • LCDR2 GAS (SEQ ID NO: 9)
  • LCDR3 GQSYNFPYT (SEQ ID NO: 10)
  • FR-H2 MNWVKQRPGQGLEWIGM (SEQ ID NO: 24)
  • FR-H3 HNNQMFKDKATLTVDKSSNTAYMHLSSLTSEDSAVYHC (SEQ ID NO: 25)
  • FR-L1 NIVMTQSPKSMSMSLGERVTLSCKAS (SEQ ID NO: 27)
  • FR-L2 VSWFQQKPHQSPKLLIY (SEQ ID NO: 28)
  • FR-L3 NRYTGVPDRFTGSGSATDFTLTISNVQAEDLADYHC (SEQ ID NO: 29)
  • FR-L4 FGGGTKLEIK (SEQ ID NO: 30)
  • FR-H2 MNWVRQRPGQGLEWIGM (SEQ ID NO: 32)
  • FR-H3 HNAQKFQGKATLTVDKSTSTAYMHLSSLRSEDTAVYYC (SEQ ID NO: 33)
  • FR-H4 WGAGTTVTVSS (SEQ ID NO: 34)
  • FR-L1 NIVMTQSPATMSMSPGERVTLSCRAS (SEQ ID NO: 35)
  • FR-L2 VSWFQQKPGQAPRLLIY (SEQ ID NO: 36)
  • FR-L3 NRYTGVPARFSGSGSGTDFTLTISSVQPEDLADYHC (SEQ ID NO: 37)
  • FR-L4 FGGGTKLEIK (SEQ ID NO: 38)
  • FR-H2 MNWVRQRPGQGLEWIGI (SEQ ID NO: 40)
  • FR-H3 SNAQKFQGRVTLTVDKSTSTAYMHLSSLRSEDTAVYYC (SEQ ID NO: 41)
  • FR-H4 WGAGTTVTVSS (SEQ ID NO: 42)
  • FR-L1 NIVMTQSPATLSLSPGERVTLSCRAS (SEQ ID NO: 43)
  • FR-L2 VSWFQQKPGQAPRLLIY (SEQ ID NO: 44)
  • FR-L3 NRATGIPARFSGSGSGTDFTLTISSLQPEDLADYYC (SEQ ID NO: 45)
  • FR-L4 FGGGTKLEIK (SEQ ID NO: 46)
  • FR-H2 MNWVRQAPGQGLEWIGI (SEQ ID NO: 48)
  • FR-H3 SYAQKFQGRVTLTVDKSTSTAYMELSSLRSEDTAVYYC (SEQ ID NO: 49)
  • FR-H4 WGAGTTVTVSS (SEQ ID NO: 50)
  • FR-L1 NIVMTQSPATLSLSPGERVTLSCRAS (SEQ ID NO: 51)
  • FR-L2 LSWYQQKPGQAPRLLIY (SEQ ID NO: 52)
  • FR-L3 TRATGIPARFSGSGSGTDFTLTISSLQPEDFAVYYC (SEQ ID NO: 53)
  • FR-L4 FGGGTKLEIK (SEQ ID NO: 54)
  • the heavy chain sequence of hIgG (SEQ ID NO: 72)
  • TEV amino acid sequence is ENLYFQG (SEQ ID NO: 74)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/CN2020/113287 2019-09-03 2020-09-03 抗cd47的单克隆抗体及其用途 Ceased WO2021043220A1 (zh)

Priority Applications (12)

Application Number Priority Date Filing Date Title
US17/640,005 US12703743B2 (en) 2019-09-03 2020-09-03 Anti-CD47 monoclonal antibody and use thereof
BR112022003868A BR112022003868A2 (pt) 2019-09-03 2020-09-03 Anticorpo, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para preparar o anticorpo, conjugado de anticorpo, anticorpo multiespecífico, proteína de fusão, kit, linhagem de células de hibridoma, usos do anticorpo, composição farmacêutica, método in vivo ou in vitro
JP2022513964A JP7808546B2 (ja) 2019-09-03 2020-09-03 抗cd47モノクローナル抗体及びその使用
EP20861103.8A EP4026847A4 (en) 2019-09-03 2020-09-03 MONOCLONAL ANTI-CD47 ANTIBODIES AND USE THEREOF
CA3148956A CA3148956A1 (en) 2019-09-03 2020-09-03 Anti-cd47 monoclonal antibody and use thereof
KR1020227010974A KR20220053665A (ko) 2019-09-03 2020-09-03 항-cd47 단일클론 항체 및 이의 용도
PH1/2022/550489A PH12022550489A1 (en) 2019-09-03 2020-09-03 Anti-cd47 monoclonal antibody and use thereof
MX2022002505A MX2022002505A (es) 2019-09-03 2020-09-03 Anticuerpo monoclonal anti-cd47 y uso del mismo.
AU2020342192A AU2020342192A1 (en) 2019-09-03 2020-09-03 Anti-CD47 monoclonal antibody and use thereof
IL291049A IL291049A (en) 2019-09-03 2022-03-02 Anti-cd47 monoclonal antibody and use thereof
ZA2022/03622A ZA202203622B (en) 2019-09-03 2022-03-29 Anti-cd47 monoclonal antibody and use thereof
JP2025072311A JP2025114620A (ja) 2019-09-03 2025-04-24 抗cd47モノクローナル抗体及びその使用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201910835819.2 2019-09-03
CN201910836601.9 2019-09-03
CN201910835819 2019-09-03
CN201910836601 2019-09-03

Publications (1)

Publication Number Publication Date
WO2021043220A1 true WO2021043220A1 (zh) 2021-03-11

Family

ID=74736180

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/113287 Ceased WO2021043220A1 (zh) 2019-09-03 2020-09-03 抗cd47的单克隆抗体及其用途

Country Status (13)

Country Link
US (1) US12703743B2 (cg-RX-API-DMAC7.html)
EP (1) EP4026847A4 (cg-RX-API-DMAC7.html)
JP (2) JP7808546B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220053665A (cg-RX-API-DMAC7.html)
CN (1) CN112442123B (cg-RX-API-DMAC7.html)
AU (1) AU2020342192A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022003868A2 (cg-RX-API-DMAC7.html)
CA (1) CA3148956A1 (cg-RX-API-DMAC7.html)
IL (1) IL291049A (cg-RX-API-DMAC7.html)
MX (1) MX2022002505A (cg-RX-API-DMAC7.html)
PH (1) PH12022550489A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021043220A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202203622B (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023191117A1 (ko) * 2022-03-28 2023-10-05 (주)이노베이션바이오 친화도가 성숙된 cd47에 특이적인 인간화 항체
JP2024515396A (ja) * 2021-04-14 2024-04-10 中山康方生物医▲藥▼有限公司 抗cd47モノクローナル抗体及びその使用
JP2025524386A (ja) * 2022-06-15 2025-07-30 中山康方生物医▲藥▼有限公司 抗cldn18.2抗体を含む二重特異性抗体、並びにその医薬組成物及び使用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025201450A1 (zh) * 2024-03-27 2025-10-02 康方汇科(上海)生物有限公司 药物组合及用途
WO2026051964A1 (en) * 2024-09-04 2026-03-12 Akeso Biopharma Co., Ltd. Antibody that binds vegfa and pd-1 and uses thereof to treat cancers

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US20150183874A1 (en) 2010-05-14 2015-07-02 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to cd47
WO2017049251A2 (en) * 2015-09-18 2017-03-23 Tioma Therapeutics, Inc. Therapeutic cd47 antibodies
CN108290948A (zh) * 2015-09-21 2018-07-17 伊拉兹马斯大学医疗中心 抗-cd47抗体及使用方法
CN109265547A (zh) * 2018-07-23 2019-01-25 中国科学院微生物研究所 一种抗cd47抗体及其应用
CN109438576A (zh) * 2018-11-14 2019-03-08 上海交通大学 一种抗人cd47单克隆抗体的制备及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015007446A (es) * 2012-12-12 2015-12-07 Vasculox Inc Anticuerpos terapeuticos para cd47.
CA3011097C (en) 2016-01-11 2022-12-20 Forty Seven, Inc. Humanized, mouse or chimeric anti-cd47 monoclonal antibodies
EP3538557A4 (en) 2016-11-08 2020-11-18 Ablexis, LLC ANTI-CD47 ANTIBODY
KR102607101B1 (ko) 2017-01-26 2023-11-29 제트엘아이피 홀딩 리미티드 Cd47 항원 결합 유닛 및 그것의 사용
MX2020001309A (es) 2017-08-02 2020-08-20 Phanes Therapeutics Inc Anticuerpos anti-cd47 y sus usos.
CN109422811A (zh) 2017-08-29 2019-03-05 信达生物制药(苏州)有限公司 抗cd47抗体及其用途
WO2019086573A1 (en) 2017-11-01 2019-05-09 Hummingbird Bioscience Holdings Pte. Ltd. Cd47 antigen-binding molecules
WO2019129054A1 (zh) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 三链抗体、其制备方法及其用途
CN111629754B (zh) 2018-01-24 2023-10-20 南京传奇生物科技有限公司 不引起显著红血细胞凝集的抗cd47抗体
KR102153197B1 (ko) 2018-12-18 2020-09-08 주식회사 포스코 가공성이 우수한 냉연강판, 용융아연도금강판 및 이들의 제조방법
CN118459587A (zh) * 2019-02-01 2024-08-09 启晨佰泰(北京)医药科技有限公司 抗cd47抗体及其应用

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US20150183874A1 (en) 2010-05-14 2015-07-02 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to cd47
WO2017049251A2 (en) * 2015-09-18 2017-03-23 Tioma Therapeutics, Inc. Therapeutic cd47 antibodies
CN108290948A (zh) * 2015-09-21 2018-07-17 伊拉兹马斯大学医疗中心 抗-cd47抗体及使用方法
CN109265547A (zh) * 2018-07-23 2019-01-25 中国科学院微生物研究所 一种抗cd47抗体及其应用
CN109438576A (zh) * 2018-11-14 2019-03-08 上海交通大学 一种抗人cd47单克隆抗体的制备及其应用

Non-Patent Citations (29)

* Cited by examiner, † Cited by third party
Title
"Epitope Mapping Protocols in Methods in Molecular Biology", vol. 66, 1996
"GenBank", Database accession no. NP 542970.1
"Molecular Cloning: A Laboratory Manual"
ALTSCHUL ET AL., MOL. BIOL., vol. 215, 1990, pages 403 - 410
ALTSCHUL, NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 402
BAI, YINPENG ET AL.: "Achievements and Concerns of the CD 47 Targeted Anti-Cancer Therapy", ZHONGGUO ZHONGLIU LINCHUANG - CHINESE JOURNAL OF CLINICAL ONCOLOGY, TIANJIN SHI YIXUE ZAZHISHE, TIANJIN, CH, vol. 44, no. 7, 15 April 2017 (2017-04-15), CH, pages 344 - 348, XP009520205, ISSN: 1000-8179 *
BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426
CLARK, IMMUNOL. TODAY, vol. 21, 2000, pages 397 - 402
GONNET ET AL., SCIENCE, vol. 256, 1992, pages 1443 - 45
HAGE TREINEMER PSEBALD W.: "Crystals of a 1:1 Complex Between Human Interleukin-4 and the Extracellular Domain of Its Receptor Alpha Chain", EUR. J. BIOCHEM., vol. 258, no. 2, 1998, pages 831 - 6, XP003018346, DOI: 10.1046/j.1432-1327.1998.2580831.x
HUSTON ET AL., PROC. NATL. ACAD. SCI., USA, vol. 90, 1988, pages 5879 - 5883
JAISWAL SJAMIESON C H MPANG W W ET AL., CELL, vol. 138, no. 3, 2009, pages 271 - 285
JIANG PLAGENAUR CFNARAYANAN V: "Integrin-associated Protein Is a Ligand for the P84 Neural Adhesion Molecule", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, 1999, pages 559 - 62
JIE LIU, WANG LIJUAN, ZHAO FEIFEI, TSENG SERENA, NARAYANAN CYNDHAVI, SHURA LEI, WILLINGHAM STEPHEN, HOWARD MAUREEN, PROHASKA SUSAN: "Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential", PLOS ONE, PUBLIC LIBRARY OF SCIENCE, vol. 10, no. 9, 21 September 2015 (2015-09-21), pages 1 - 23, XP055223677, DOI: 10.1371/journal.pone.0137345 *
JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525
KOHLER, NATURE, vol. 256, 1975, pages 495
KOSTELNY ET AL., J. IMMUNOL., vol. 148, pages 1547 - 1553
LIU JIANJUN, CHINESE JOURNAL OF CELLULAR AND MOLECULAR IMMUNOLOGY, vol. 4, 1989, pages 29 - 29
MATOZAKI TMURATA YOKAZAWA H ET AL.: "Functions and molecular mechanisms of the CD47-SIRPa signalling pathway", TRENDS IN CELL BIOLOGY, vol. 19, no. 2, 2009, pages 72 - 80, XP025913010, DOI: 10.1016/j.tcb.2008.12.001
OLDENBORG P AZHELEZNYAK AFANG Y F ET AL.: "Role of CD47 as a marker of self on red blood cells", SCIENCE, vol. 288, no. 5473, 2000, pages 2051 - 2054, XP055304810, DOI: 10.1126/science.288.5473.2051
PEARSON, METHODS ENZYMOL., vol. 183, 1990, pages 63 - 98
PEARSON, METHODS MOL. BIOL., vol. 132, 2000, pages 185 - 219
PEARSON, METHODS MOL. BIOL., vol. 243, 1994, pages 307 - 31
PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593 - 596
REICHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329
See also references of EP4026847A4
SONGSIVILAILACHMANN, CLIN. EXP. IMMUNOL., vol. 79, 1990, pages 315 - 321
VONDERHEIDE R H., NATURE MEDICINE, vol. 21, no. 10, 2015, pages 1122
WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024515396A (ja) * 2021-04-14 2024-04-10 中山康方生物医▲藥▼有限公司 抗cd47モノクローナル抗体及びその使用
WO2023191117A1 (ko) * 2022-03-28 2023-10-05 (주)이노베이션바이오 친화도가 성숙된 cd47에 특이적인 인간화 항체
JP2025524386A (ja) * 2022-06-15 2025-07-30 中山康方生物医▲藥▼有限公司 抗cldn18.2抗体を含む二重特異性抗体、並びにその医薬組成物及び使用
EP4541821A4 (en) * 2022-06-15 2026-06-03 Akeso Biopharma Inc Bispecific antibody containing an anti-CLDN18.2 antibody, pharmaceutical composition and associated use
JP7892081B2 (ja) 2022-06-15 2026-07-17 中山康方生物医▲藥▼有限公司 抗cldn18.2抗体を含む二重特異性抗体、並びにその医薬組成物及び使用

Also Published As

Publication number Publication date
EP4026847A1 (en) 2022-07-13
EP4026847A4 (en) 2024-01-10
US20220324971A1 (en) 2022-10-13
MX2022002505A (es) 2022-06-02
PH12022550489A1 (en) 2022-12-12
JP7808546B2 (ja) 2026-01-29
ZA202203622B (en) 2024-01-31
CA3148956A1 (en) 2021-03-11
AU2020342192A1 (en) 2022-04-21
CN112442123A (zh) 2021-03-05
IL291049A (en) 2022-05-01
BR112022003868A2 (pt) 2022-05-31
CN112442123B (zh) 2022-08-23
JP2022545974A (ja) 2022-11-01
JP2025114620A (ja) 2025-08-05
US12703743B2 (en) 2026-08-11
KR20220053665A (ko) 2022-04-29

Similar Documents

Publication Publication Date Title
US12479919B2 (en) Anti-CTLA4 and anti-PD-1 bifunctional antibody, pharmaceutical composition thereof and use thereof
CN111647082B (zh) 抗人il-4ra的抗体及其用途
CN110382536B (zh) 抗pd-1抗体及其用途
TWI801862B (zh) 抗tigit的抗體、其製備方法和應用
JP5677744B2 (ja) ヒトDelta様リガンド4に対するヒト抗体
CN112442123B (zh) 抗cd47的单克隆抗体及其用途
JP2019107018A (ja) 抗ctla4モノクローナル抗体またはその抗原結合断片、医薬組成物および使用
WO2023151693A1 (zh) 包含抗tigit抗体和抗pd-1-抗vegfa双特异性抗体的药物组合物及用途
WO2022218384A1 (zh) 抗cd47的单克隆抗体及其用途
CN114981301A (zh) Pd1和vegfr2双结合剂
WO2022089392A1 (zh) 抗tigit抗体、其药物组合物及用途
WO2023208104A1 (zh) 抗人il-4ra的抗体及其用途
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
CN115996951A (zh) 抗cd103抗体
KR20220050182A (ko) 항-cd22 항체 및 그의 용도
WO2023052541A1 (en) Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
KR20220048028A (ko) 항-cd19 항체 및 그의 용도
HK40076698A (en) Anti-cd47 monoclonal antibody and use thereof
EA051039B1 (ru) Анти-cd47 моноклональное антитело и его применение
WO2024153146A1 (zh) 抗nmda受体自身免疫性脑炎新型抗体及其用途
WO2023173393A1 (zh) 结合b7-h3的抗体及其用途
CN121005780A (zh) 靶向hla-g的抗体或其抗原结合片段及其应用
CN117285628A (zh) 抗vista抗体及其应用
HK40076989A (en) Anti-cd22 antibodies and uses thereof
TW202411252A (zh) 抗pd-1抗體及其用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20861103

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3148956

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2022513964

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022003868

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20227010974

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2020861103

Country of ref document: EP

Effective date: 20220404

ENP Entry into the national phase

Ref document number: 2020342192

Country of ref document: AU

Date of ref document: 20200903

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112022003868

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20220302